Corpus interruptus: Biotech drugs, insurance providers and the treatment of breast cancer [Book Review]
David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Journal of Bioethical Inquiry 4 (2):103-103 (2007)
In researching the biomedically-engineered drug Neulasta (filgrastim), a breast cancer patient becomes aware of the extent to which knowledge about the development and marketing of drugs influences her decisions with regard to treatment. Time spent on understanding the commercial interests of insurers and pharmaceutical companies initially thwarts but ultimately aids the healing process. This first-person narrative calls for physicians to recognize that the alignment of commercial interests transgresses the patient’s humanity
|Keywords||Survivors Breast neoplasms Filgrastim Drug Industry Narration|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
Lisa S. Parker (1995). Breast Cancer Genetic Screening and Critical Bioethics' Gaze. Journal of Medicine and Philosophy 20 (3):313-337.
Matt Williams & Jon Williamson (2006). Combining Argumentation and Bayesian Nets for Breast Cancer Prognosis. Journal of Logic, Language and Information 15 (1-2):155-178.
Jon Williamson (2006). Combining Argumentation and Bayesian Nets for Breast Cancer Prognosis. Journal of Logic, Language and Information 15 (1-2):155-178.
Mary Twomey (2011). Relational Autonomy: An Example From Breast Cancer Nursing. Ethics and Social Welfare 5 (4):408-413.
L. Rosenblatt (2006). Being the Monster: Women's Narratives of Body and Self After Treatment for Breast Cancer. Medical Humanities 32 (1):53-56.
Susan Gilbert (2010). Personalized Cancer Care in an Age of Anxiety. Hastings Center Report 40 (5):18-21.
E. Fenton (2010). Making Fair Funding Decisions for High Cost Cancer Care: The Case of Herceptin in New Zealand. Public Health Ethics 3 (2):137-146.
Don Marquis (1989). An Ethical Problem Concerning Recent Therapeutic Research on Breast Cancer. Hypatia 4 (2):140 - 155.
Roy Gilbar & Ora Gilbar (2009). The Medical Decision-Making Process and the Family: The Case of Breast Cancer Patients and Their Husbands. Bioethics 23 (3):183-192.
Added to index2009-01-28
Total downloads3 ( #313,528 of 1,140,108 )
Recent downloads (6 months)1 ( #147,976 of 1,140,108 )
How can I increase my downloads?